Drugs unproven of its bio-equivalency to exit in 2007

Published: 2003-01-20 07:00:00

Updated: 2003-01-20 07:00:00

The KFDA policy prescribes that the drug without bio-equivalency proof should gradually exit from the market through the suspension of sales or cancellation of product registration starting from 2007 for the purpose of encouraging the substituted dispensing at pharmacies.

The new provisions ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK